CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation

NYSE:CRL • US1598641074

Current stock price

166.06 USD
-2.16 (-1.28%)
Last:

This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. CRL Profitability Analysis

1.1 Basic Checks

  • In the past year CRL was profitable.
  • CRL had a positive operating cash flow in the past year.
  • CRL had positive earnings in 4 of the past 5 years.
  • In the past 5 years CRL always reported a positive cash flow from operatings.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • With a Return On Assets value of -2.02%, CRL perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
  • The Return On Equity of CRL (-4.56%) is comparable to the rest of the industry.
  • CRL's Return On Invested Capital of 6.60% is fine compared to the rest of the industry. CRL outperforms 77.19% of its industry peers.
  • CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is below the industry average of 11.38%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • CRL has a Operating Margin of 12.51%. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • In the last couple of years the Operating Margin of CRL has declined.
  • CRL has a worse Gross Margin (34.98%) than 63.16% of its industry peers.
  • CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRL Health Analysis

2.1 Basic Checks

  • CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CRL has been reduced compared to 1 year ago.
  • CRL has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CRL has a worse debt to assets ratio.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • CRL has an Altman-Z score of 2.37. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of CRL (2.37) is better than 61.40% of its industry peers.
  • CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.13, CRL is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
  • CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
  • CRL has a Debt to Equity ratio of 0.68. This is in the lower half of the industry: CRL underperforms 70.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.37
ROIC/WACC0.63
WACC10.51%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.29, CRL is not doing good in the industry: 82.46% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.02, CRL is doing worse than 82.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRL Growth Analysis

3.1 Past

  • CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
  • The Earnings Per Share has been growing slightly by 4.78% on average over the past years.
  • CRL shows a decrease in Revenue. In the last year, the revenue decreased by -0.85%.
  • Measured over the past years, CRL shows a small growth in Revenue. The Revenue has been growing by 6.55% on average per year.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.31% on average over the next years. This is quite good.
  • CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.54% yearly.
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

6

4. CRL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.15, which indicates a correct valuation of CRL.
  • CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 92.98% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.21. CRL is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 14.89, CRL is valued correctly.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 91.23% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.13. CRL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.15
Fwd PE 14.89
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.74% of the companies listed in the same industry.
  • CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 89.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.77
EV/EBITDA 11.27
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)1.91
PEG (5Y)3.38
EPS Next 2Y8.74%
EPS Next 3Y8.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRL Dividend Analysis

5.1 Amount

  • No dividends for CRL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRL Fundamentals: All Metrics, Ratios and Statistics

CHARLES RIVER LABORATORIES

NYSE:CRL (4/7/2026, 11:23:23 AM)

166.06

-2.16 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners110.03%
Inst Owner Change-0.02%
Ins Owners0.94%
Ins Owner Change5.84%
Market Cap8.18B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.34 (24.26%)
Short Float %7.72%
Short Ratio3.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)0.03%
PT rev (3m)2.47%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)0%
EPS NY rev (3m)1.64%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)-1.82%
Revenue NY rev (1m)-1.88%
Revenue NY rev (3m)-2.26%
Valuation
Industry RankSector Rank
PE 16.15
Fwd PE 14.89
P/S 2.04
P/FCF 15.77
P/OCF 11.08
P/B 2.58
P/tB 135.39
EV/EBITDA 11.27
EPS(TTM)10.28
EY6.19%
EPS(NY)11.15
Fwd EY6.71%
FCF(TTM)10.53
FCFY6.34%
OCF(TTM)14.98
OCFY9.02%
SpS81.56
BVpS64.28
TBVpS1.23
PEG (NY)1.91
PEG (5Y)3.38
Graham Number121.94
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.37
F-Score5
WACC10.51%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year-0.59%
Revenue Next 2Y1.18%
Revenue Next 3Y2.21%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.47%
EBIT Next 3Y11.29%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


Can you provide the profitability details for CHARLES RIVER LABORATORIES?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 16.15 and the Price/Book (PB) ratio is 2.58.


What is the financial health of CHARLES RIVER LABORATORIES (CRL) stock?

The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.